OLE Study With Filgotinib in JIA

This OLE study is designed to evaluate long-term safety, tolerability, and efficacy of filgotinib in patients with polyarticular or systemic juvenile idiopathic arthritis (pJIA-sJIA) who have completed the treatment period/prolonged treatment period of the parent studies and demonstrated clinical benefit defined as control of disease activity through improvement in signs and symptoms as per Investigator judgement.

NCT Number	NCT07553182
Lead Sponsor	Alfasigma S.p.A.
Conditions	Juvenile Idiopathic Arthritis (JIA)
Enrollment	80 participants
Start Date	2026-04-20
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-10